In addition, PSMA expression is regulated by AR signaling, which is modulated by several prostate cancer therapies as part of disease management.15,16 Accordingly, additional targets are needed to support the introduction of novel therapies that are less dependent on AR signaling, DNA repair, or PSMA, and expand the mCRPC treatment landscape. This evidence concerns the gene FOLH1 and prostate cancer.